Insider · CIK 0001895592
Sara Kenkare-Mitra
Files at ALEC (Alector, Inc.), UNCY (Unicycive Therapeutics, Inc.). First filing Dec 3, 2024, latest Dec 3, 2025.
In brief
Sara Kenkare-Mitra files SEC Form 4 as president and director at ALEC (Alector, Inc.), and also at UNCY (Unicycive Therapeutics, Inc.). Since Dec 3, 2024, Sara Kenkare-Mitra has reported 0 open-market buys worth $0 and 5 open-market sells worth $247k, the latest filed on Dec 3, 2025.
A track record needs three past buys with six months of prices behind them; Sara Kenkare-Mitra has 0, so none is measured yet.
The newest scored trade: sold $47k of ALEC on Dec 3, 2025, filed Dec 3, 2025, scored 41 (moderate). In the last 12 months: 0 buys worth $0 and 1 sell worth $47k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
ALEC: Alector, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 41Moderate | Alector, Inc. | $47k 41,687 shares | -8% | +26% from low-66% from high | |
| 42Moderate | Alector, Inc. | $59k 23,638 shares | -4% | +187% from low-58% from high | |
| 40Moderate | Alector, Inc. | $32k 23,890 shares | -4% | +53% from low-78% from high | |
| 41Moderate | Alector, Inc. | $43k 29,073 shares | -5% | 0% from low-77% from high | |
| 43Moderate | Alector, Inc. | $67k 26,500 shares | -4% | - |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Dec 1, 2025 | ALEC Alector, Inc. | 36,914 0.03% of outstanding | $45k | Dec 1, 2025 | $59k |
| Aug 29, 2025 | ALEC Alector, Inc. | 23,019 0.02% of outstanding | $54k | Sep 2, 2025 | $32k |
| May 30, 2025 | ALEC Alector, Inc. | 23,020 0.02% of outstanding | $31k | Jun 2, 2025 | $43k |
| Feb 28, 2025 | ALEC Alector, Inc. | 25,516 0.03% of outstanding | $42k | Mar 3, 2025 | $67k |
| Nov 29, 2024 | ALEC Alector, Inc. | 25,465 0.03% of outstanding | $66k | Dec 2, 2024 | $68k |
| Dec 1, 2023 | ALEC Alector, Inc. | 12,519 0.01% of outstanding | $70k | Dec 4, 2023 | $32k |
Transactions
Every row this insider has filed, 13 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| May 14, 2026 | UNCY Unicycive Therapeutics, Inc. | AGrant or award Restricted Stock Unitsderivative | +47,941 | $0.00 | $0 | 47,941 | Jul 28, 2026 |
| May 14, 2026 | UNCY Unicycive Therapeutics, Inc. | AGrant or award Restricted Stock Unitsderivative | +84,200 | $0.00 | $0 | 84,200 | Jun 15, 2026 |
| May 14, 2026 | UNCY Unicycive Therapeutics, Inc. | AGrant or award Restricted Stock Unitsderivative | +42,100 | $0.00 | $0 | 126,300 | Jun 15, 2026 |
| May 14, 2026 | UNCY Unicycive Therapeutics, Inc. | AGrant or award Restricted Stock Unitsderivative | +84,200 | $0.00 | $0 | 84,200 | May 21, 2026 |
| May 14, 2026 | UNCY Unicycive Therapeutics, Inc. | AGrant or award Restricted Stock Unitsderivative | +42,100 | $0.00 | $0 | 126,300 | May 21, 2026 |
| Dec 3, 2025 | ALEC Alector, Inc. | SOpen-market sale Common Stock | -41,687 | $1.12 | $47k | 501,652 | Dec 3, 2025 |
| Sep 2, 2025 | ALEC Alector, Inc. | SOpen-market sale Common Stock | -23,638 | $2.50 | $59k | 543,339 | Sep 4, 2025 |
| Jul 28, 2025 | UNCY Unicycive Therapeutics, Inc. | AGrant or award Stock Optionsderivative | +21,200 | $0.00 | $0 | 39,200 | Jul 30, 2025 |
| Jul 1, 2025 | ALEC Alector, Inc. | AGrant or award Common Stock | +54,725 | $0.00 | $0 | 566,977 | Jul 1, 2025 |
| Jul 1, 2025 | ALEC Alector, Inc. | AGrant or award Employee Stock Option (right to buy)derivative | +18,250 | $0.00 | $0 | 18,250 | Jul 1, 2025 |
| Jun 2, 2025 | ALEC Alector, Inc. | SOpen-market sale Common Stock | -23,890 | $1.34 | $32k | 512,252 | Jun 4, 2025 |
| Mar 3, 2025 | ALEC Alector, Inc. | SOpen-market sale Common Stock | -29,073 | $1.47 | $43k | 536,142 | Mar 5, 2025 |
| Dec 2, 2024 | ALEC Alector, Inc. | SOpen-market sale Common Stock | -26,500 | $2.52 | $67k | 565,215 | Dec 3, 2024 |
Questions about Sara Kenkare-Mitra
Answered from the filings on this page, as of the latest one.
Is Sara Kenkare-Mitra buying or selling?
In the last 12 months Sara Kenkare-Mitra reported 0 open-market buys worth $0 and 1 open-market sell worth $47k on SEC Form 4; the latest was sold $47k of ALEC on Dec 3, 2025. Grants, option exercises and tax withholding are not counted.
How did Sara Kenkare-Mitra's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Sara Kenkare-Mitra has 0.
Where does Sara Kenkare-Mitra file Form 4?
Sara Kenkare-Mitra has filed Form 4 at ALEC (Alector, Inc.) as President and Head of R&D; UNCY (Unicycive Therapeutics, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.